XTL Biopharmaceuticals Ltd. (XTLB)
XTL Biopharmaceuticals Ltd. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
XTL Biopharmaceuticals Ltd. (XTLB) is a Biotechnology company based in IL with a market capitalization of $7M. Free cash flow was negative at -$1.7M. This page tracks XTLB's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
IL · 10 employees · IPO Sep 1, 2005
Valuation
Valuation & price
$2.61as of May 17, 2026· -68.2% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
1.28
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$7M
Market cap
—
Revenue growth (YoY)
0.7%
Gross margin
-$1.7M
Free cash flow (USD)
-$1M
Net debt
Net cash position
23.5%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2015 → 2024
Free cash flow by year
2015 → 2024
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 20-F filed Jun 30, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 6-K filingJul 21, 2026Filing
Regulatory Update
- Annual reportJun 30, 2026Filing
20-F Filed
- 6-K filingJun 30, 2026Filing
Acquisition Completed
- Annual reportJun 29, 2026Filing
Annual Report Filed
- 6-K filingJun 23, 2026Filing
Extraordinary General Meeting
- 6-K filingMay 22, 2026Filing
Regulatory Update
- 6-K filingMay 15, 2026Filing
Extraordinary General Meeting Notice
- 6-K filingMay 7, 2026Filing
Regulatory Update
- 6-K filingApr 29, 2026Filing
Share Purchase Agreement
Questions
Frequently asked questions
What is XTL Biopharmaceuticals Ltd.'s market cap?
XTL Biopharmaceuticals Ltd. (XTLB) has a market capitalization of $7M.
What is XTLB's P/E ratio?
A meaningful P/E ratio is not available for XTLB — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is XTLB's price-to-book (P/B) ratio?
XTLB trades at 1.28 times book value per share.
Are insiders buying XTLB stock?
SEC Form 4 filings show no open-market insider buys at XTL Biopharmaceuticals Ltd. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.